[Press Release] Cytiva and Pall Corporation investing 1.5 billion USD over two years to meet growing…
Cytiva and Pall Corporation
investing 1.5 billion USD over two years to meet growing demand for
biotechnology solutions l Major investments are expanding manufacturing
capacity for life sciences products at 13 Cytiva and Pall Corporation sites
helping to meet customer demand. l New sites opening in US and UK to realize regional
manufacturing models. Overall, the companies plan to hire 2000 full-time
associates over the next two years.
l Investment follows five strategic acquisitions
made by the companies this year and is in addition to Cytiva’s continuing
capacity investments estimated at 500 million USD through 2022.
July 27, 2021
An ongoing strategic growth
plan from Cytiva and Pall Corporation, part of the Danaher (NYSE: DHR)
Corporation, will expand manufacturing capacity and services across geographies
for global life sciences customers.
The investment, already
underway, includes new sites, expansion at existing factories, and is
additional to previously announced investments. It follows five acquisitions
made by the companies so far this year. Emmanuel Ligner, Danaher
Group Executive, says: “Our customers tell us they need access to manufacturing
agility, a robust global supply chain and more regional options. This
investment further fuels our expansion program so we can rapidly meet the
current and future needs of our customers and ultimately, their patients.” Cytiva and Pall
Corporation’s capacity expansion will increase the manufacture of key products
used to make biologic medicines.
The companies are
investing:
l 600+ million USD in chromatography resins – media
for analyzing or purifying biomolecules – establishing a new manufacturing site
in the US. l 400+ million USD in cell culture media – in liquid
or powder form this is used to grow and cultivate cells before they are
purified– expand operations in the US, UK, and Austria. l 300+ million USD in single-use technologies –
including bioreactor bags for growing cells used to make personalized medicines
and syringe filters for scientific research – expand operations in the US and
the UK, as well as fitting out a new facility in Cardiff, Wales. l 200+ million USD for continuing expansion work in
Cytiva and Pall Corporation’s sites across China and the rest of the
Asia-Pacific region, Europe, and the US.
l This investment also addresses some of the key
challenges highlighted in the Global Biopharma Resilience Index, conducted by
Longitude, a Financial Times company, and published by Cytiva in March 2021.
These include hiring and training talent, R&D collaboration, supply chain
resilience, manufacturing models, as well as government policy and regulation.
Rapid expansion program
Funds are being allocated
to accelerate capacity expansion plans already underway at 13 Pall Corporation
and Cytiva sites making biotechnology products for COVID-19 and other critical
programs.For example, production of
cell culture media at Cytiva’s site in Logan, Utah is planned to double in
2023. This will be done by converting 25 000 m2 of land into new manufacturing
lines, distribution hubs, and clean rooms as well as creating 250 new jobs
locally. Combined with the acquisition of Intermountain Life Sciences, a
manufacturer of liquid cell culture media and buffers, customers being supplied
out of Logan will see shorter lead times in delivery of those products. Additionally, investments
at Pall sites in Newquay, UK, Pensacola, FL, and San Diego, CA have increased
capacity to make and deliver membrane and filter products. The 1.5 billion USD
investment follows Cytiva’s announcement in 2020 to spend 500 million USD
building capacity. The investment has already funded a new manufacturing
facility in Shrewsbury, MA and a new cleanroom in Westborough, MA in the US. A
new cell and gene therapy manufacturing site and Center of Excellence is
scheduled to open in Switzerland in 2022. As part of today’s
investment, Pall Corporation will expand single-use manufacturing operations in
China at the site of recently acquired Austar. Plans are also underway to
expand Cytiva’s partnership with Wego in China to build more single-use
technology manufacturing capacity for the region. Both companies plan for
further regional investment in the future.
New facilities
A new 11 000 m2 facility in
Cardiff, Wales, is being fitted out to manufacture single-use bioprocessing
equipment including jumper tubing assemblies, cell bags, and ÄKTA flow kits.
The first products are expected to be manufactured at this site before the end
of 2021. A local hiring drive has begun to fill 250 new jobs over the next two
years, primarily in manufacturing, as well as warehouse operators, material
handlers, and R&D scientists. The vision for the new US
facility is to replicate and complement Cytiva’s leading resin manufacturing
capabilities at its site in Uppsala, Sweden. The location of the new site will
be announced at a later date. Cytiva plans to hire 400 people in the US and
Sweden over the next two years to facilitate expansion plans.
Investing in talent
Overall, the companies are
planning to hire 2000 people over the next two years to support growth. This is
additional to the 2000 new associates hired by Cytiva and Pall Corporation over
the last year. The approach considers the
well-established skills gap in the biotechnology industry. For example,
training for manufacturing roles will involve intensive on-site courses.
Onboarding for highly technical roles will leverage Cytiva’s FastTrak centers
and online training designed in partnership with the National Institute for
Bioprocessing Research and Training (NIBRT) in Dublin, Ireland.
Acquiring automation and
digital capabilities
Supporting the
biotechnology industry through rapid growth requires access to innovative
technologies as well as manufacturing capacity.
Ligner says: “We envision a
world in which access to life-changing therapies transforms human health. Our
investments and acquisitions are about building capacity and the therapeutic
development workflow to advance and accelerate the work of our customers.”
Recent acquisitions by Pall
Corporation and Cytiva include:
l Vanrx Pharmasystems, Canada (Acquired by Cytiva in
February 2021) Drug product aseptic filling solutions which automate the
preparation of small batches of biologic medicines, well suited to the
manufacture of cell and gene therapies. l Austar, China (Acquired by Pall in March 2021)
Additional single-use technology manufacturing capabilities in China to help
meet need for regional vaccine manufacturing, driven by COVID-19. l GoSilico, Germany (Acquired by Cytiva in June
2021) Mechanistic modelling software to create “digital twin” simulations of
downstream bioprocessing steps for more efficient chromatography and drug
manufacturing process development. l Precision NanoSystems, Canada (Acquired by Pall in
June 2021) Manufacturing and development of lipid nanoparticles for the
delivery of genetic medicines, including mRNA vaccines and therapeutics.
l Intermountain Life Sciences (Acquired by Cytiva in
June 2021) A new fully-operational manufacturing site in Logan, Utah will
rapidly boost liquid cell culture media production by millions of liters.
Learn more: Read the
industry insights uncovered in Cytiva’s Biopharma Resilience Index. Explore
Pall Corporation’s Biotech Solutions. About Pall
Pall Corporation is a
filtration, separation and purification leader providing solutions to meet the
critical fluid management needs of customers across the broad spectrum of life
sciences and industry. Part of the Danaher (NYSE: DHR) family of science and
technology innovators, Pall works with customers to advance health, safety and
environmentally responsible technologies. The Company’s engineered products
enable process and product innovation and minimize emissions and waste. Pall
Corporation serves customers worldwide. For more information visit
www.pall.com.
About Cytiva
Cytiva is a global life
sciences leader with more than 8,000 associates across 40 countries dedicated
to advancing and accelerating therapeutics. Part of the Danaher (NYSE: DHR)
family of science and technology innovators, Cytiva is a trusted partner to
customers that range in scale and scope, Cytiva brings speed, efficiency and
capacity to research and manufacturing workflows, enabling the development,
manufacture and delivery of transformative medicines to patients. For more information
visit www.cytiva.com.
Media contact:
Dodi Axelson
Dodi.axelson@cytiva.comSource: www.cytivalifesciences.com/en/us/news-center/investing-for-capacity-expansion-2021-10001
2021.07.28
>
>
